Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cyanokit, indicated for the treatment of known or suspected cyanide poisoning, typically caused by smoke inhalation from fire
Subscribe to our email newsletter
King Pharmaceuticals (King) has licensed from Merck Sante, an affiliate of Germany-based Merck KGaA, the exclusive rights to market and sell Cyanokit 5g (hydroxocobalamin for injection) Antidote in the US. Cyanokit is indicated for the treatment of known or suspected cyanide poisoning, typically caused by smoke inhalation from fires.
The company said that Cyanokit will be sold and distributed through Meridian Medical Technologies, a wholly-owned subsidiary of King.
Reportedlty, Cyanokit’s active ingredient is hydroxocobalamin, which forms a strong bond with cyanide, converting it to vitamin B12, which can then be safely excreted from the body. It is designed specifically to be used on the scene or at the hospital for acute cyanide poisoning, or suspected poisoning, from any source.
Brian Markison, chairman, president and CEO of King, said: “Cyanokit is well-suited to King’s existing line of acute care products. Our portfolio of antidotes currently serves the emergency medical services community, as well as the US Department of Defense and other federal, state and local agencies.”